Optimised modular anti-FLAG CAR T cells for solid tumor therapy.

Area of Science:

• Immunotherapy
• Oncology
• Molecular Engineering

Background:

• Chimeric antigen receptor (CAR) T-cell therapies are effective against B cell malignancies but face challenges in solid tumors, including antigen escape and heterogeneity.
• Current CAR T-cell limitations hinder broader application in treating complex diseases like solid cancers.

Purpose of the Study:

• To develop a novel anti-FLAG CAR T-cell system for flexible targeting of solid tumors.
• To engineer a modular CAR T-cell platform capable of engaging secondary FLAG-tagged reagents for adaptable cancer therapy.

Main Methods:

• Engineered a humanized anti-FLAG CAR, optimizing its structure to mitigate tonic signaling and exhaustion.
• Assessed therapeutic efficacy in solid tumor mouse models using FLAG-engineered tumor cells and FLAG-tagged secondary targeting reagents.

Main Results:

• Initial anti-FLAG CAR constructs showed functional activity but suffered from tonic signaling and exhaustion.
• Structural optimization significantly reduced CAR T-cell exhaustion, enhancing persistence and functionality.
• Optimized CAR T-cells demonstrated effective inhibition of tumor growth in preclinical models.

Conclusions:

• CAR design is critical for minimizing T-cell exhaustion and maximizing therapeutic efficacy.
• This modular CAR T-cell platform shows potential for overcoming antigen heterogeneity and immune evasion in solid tumors.
• The anti-FLAG CAR system offers a flexible and adaptable strategy for next-generation cancer immunotherapies.